{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T13:54:47Z","timestamp":1722347687437},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00108-018-0508-0","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T13:13:10Z","timestamp":1538053990000},"page":"1335-1343","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Neue \u03b2\u2011Laktam-Antibiotika und \u03b2\u2011Laktamase-Inhibitoren gegen multiresistente Gram-negative Erreger"],"prefix":"10.1007","volume":"59","author":[{"given":"Alexander","family":"Mischnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico T.","family":"Mutters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"508_CR1","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijantimicag.2015.08.011","volume":"46","author":"K Bush","year":"2015","unstructured":"Bush K (2015) A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483\u2013493","journal-title":"Int J Antimicrob Agents"},{"key":"508_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10928-017-9506-4","volume":"44","author":"K Bush","year":"2017","unstructured":"Bush K, Page MGP (2017) What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles. J\u00a0Pharmacokinet Pharmacodyn 44:113\u2013132","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"508_CR3","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.02462-13","volume":"58","author":"G Cabot","year":"2014","unstructured":"Cabot G, Bruchmann S, Mulet X et al (2014) Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 58:3091\u20133099","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE). Lancet Infect Dis 16:661\u2013673 (a\u00a0randomised, pathogen-directed, phase 3 study)","journal-title":"Lancet Infect Dis"},{"key":"508_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jmii.2010.06.001","volume":"44","author":"HJ Chang","year":"2011","unstructured":"Chang HJ, Hsu PC, Yang CC et al (2011) Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a\u00a0matched case-control study. J\u00a0Microbiol Immunol Infect 44:125\u2013130","journal-title":"J Microbiol Immunol Infect"},{"key":"508_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA (2014) New beta-lactamase inhibitors: a\u00a0therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835\u20131846","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.diagmicrobio.2014.07.005","volume":"80","author":"RK Flamm","year":"2014","unstructured":"Flamm RK, Sader HS, Farrell DJ, Jones RN (2014) Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a\u00a0global surveillance program (2011). Diagn Microbiol Infect Dis 80:233\u2013238","journal-title":"Diagn Microbiol Infect Dis"},{"key":"508_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02101-17","author":"MJ Giddins","year":"2018","unstructured":"Giddins MJ, Macesic N, Annavajhala MK et al (2018) Successive emergence of Ceftazidime-Avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02101-17","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR9","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/jac\/dkw053","volume":"71","author":"JA Huntington","year":"2016","unstructured":"Huntington JA, Sakoulas G, Umeh O et al (2016) Efficacy of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J\u00a0Antimicrob Chemother 71:2014\u20132021","journal-title":"J Antimicrob Chemother"},{"key":"508_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","volume":"71","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK et al (2016) In vitro antimicrobial activity of S\u2011649266, a\u00a0catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J\u00a0Antimicrob Chemother 71:670\u2013677","journal-title":"J Antimicrob Chemother"},{"key":"508_CR11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/JCM.34.4.908-911.1996","volume":"34","author":"GA Jacoby","year":"1996","unstructured":"Jacoby GA, Han P (1996) Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J\u00a0Clin Microbiol 34:908\u2013911","journal-title":"J Clin Microbiol"},{"key":"508_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S et al (2018) Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA 319:788\u2013799","journal-title":"JAMA"},{"key":"508_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00449-17","author":"M King","year":"2017","unstructured":"King M, Heil E, Kuriakose S et al (2017) Multicenter study of outcomes with Ceftazidime-Avibactam in patients with Carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00449-17","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR14","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","volume":"60","author":"N Kohira","year":"2016","unstructured":"Kohira N, West J, Ito A et al (2016) In vitro antimicrobial activity of a\u00a0Siderophore Cephalosporin, S\u2011649266, against Enterobacteriaceae clinical isolates, including Carbapenem-resistant strains. Antimicrob Agents Chemother 60:729\u2013734","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR15","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.1128\/AAC.00830-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O et al (2015) Activity of Imipenem with Relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother 59:5029\u20135031","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR16","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O et al (2015) Activity of Meropenem combined with RPX7009, a\u00a0novel beta-Lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856\u20134860","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1128\/AAC.04191-14","volume":"59","author":"H Li","year":"2015","unstructured":"Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K (2015) In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59:1789\u20131793","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR18","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D et al (2016) Phase 2, dose-ranging study of Relebactam with Imipenem-Cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234\u20136243","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J et al (2016) Efficacy and safety of Ceftazidime-Avibactam plus Metronidazole versus Meropenem in the treatment of complicated intra-abdominal infection: results from a\u00a0randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380\u20131389","journal-title":"Clin Infect Dis"},{"key":"508_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1055\/s-0041-100105","volume":"140","author":"A Mischnik","year":"2015","unstructured":"Mischnik A, Kaase M, Lubbert C, Seifert H, Kern WV (2015) Carbapenem-resistance in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii. Dtsch Med Wochenschr 140:172\u2013176","journal-title":"Dtsch Med Wochenschr"},{"key":"508_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10534-009-9219-2","volume":"22","author":"U Mollmann","year":"2009","unstructured":"Mollmann U, Heinisch L, Bauernfeind A, Kohler T, Ankel-Fuchs D (2009) Siderophores as drug delivery agents: application of the \u201cTrojan Horse\u201d strategy. Biometals 22:615\u2013624","journal-title":"Biometals"},{"key":"508_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cmi.2015.06.007","volume":"21","author":"AE Muller","year":"2015","unstructured":"Muller AE, Theuretzbacher U, Mouton JW (2015) Use of old antibiotics now and in the future from a\u00a0pharmacokinetic\/pharmacodynamic perspective. Clin Microbiol Infect 21:881\u2013885","journal-title":"Clin Microbiol Infect"},{"key":"508_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cix014","volume":"65","author":"JM Munita","year":"2017","unstructured":"Munita JM, Aitken SL, Miller WR et al (2017) Multicenter evaluation of Ceftolozane\/Tazobactam for serious infections caused by Carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 65:158\u2013161","journal-title":"Clin Infect Dis"},{"key":"508_CR24","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jac\/dkx009","volume":"72","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Bassetti M, Duncan LR, Castanheira M (2017) Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in europe: report from an antimicrobial surveillance programme (2012\u201315). J\u00a0Antimicrob Chemother 72:1386\u20131395","journal-title":"J Antimicrob Chemother"},{"key":"508_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"JD Pitout","year":"2008","unstructured":"Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:159\u2013166","journal-title":"Lancet Infect Dis"},{"key":"508_CR26","doi-asserted-by":"crossref","unstructured":"Portsmouth S, Vennhuyzen D, Echols R, Machida M, Ferrreira JCA et al (2017) Cefiderocol compared with imipenem\/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicentre, doubleblind, randomized study. Presented at 27th European Congress of Clinical Microbiology and Infectious Diseases, April 2017 Vienna","DOI":"10.1093\/ofid\/ofx163.1399"},{"key":"508_CR27","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/jac\/dku184","volume":"69","author":"HS Sader","year":"2014","unstructured":"Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN (2014) Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312). J\u00a0Antimicrob Chemother 69:2713\u20132722","journal-title":"J Antimicrob Chemother"},{"key":"508_CR28","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","volume":"73","author":"E Shaw","year":"2018","unstructured":"Shaw E, Rombauts A, Tubau F et al (2018) Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection. J\u00a0Antimicrob Chemother 73:1104\u20131106","journal-title":"J Antimicrob Chemother"},{"key":"508_CR29","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1128\/AAC.00548-15","volume":"59","author":"RK Shields","year":"2015","unstructured":"Shields RK, Clancy CJ, Hao B et al (2015) Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother 59:5793\u20135797","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR30","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G et al (2016) Clinical outcomes, drug toxicity, and emergence of Ceftazidime-Avibactam resistance among patients treated for Carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615\u20131618","journal-title":"Clin Infect Dis"},{"key":"508_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17","author":"RK Shields","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L et al (2017) Ceftazidime-Avibactam is superior to other treatment regimens against Carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00883-17","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR32","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims M, Mariyanovski V, McLeroth P et al (2017) Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J\u00a0Antimicrob Chemother 72:2616\u20132626","journal-title":"J Antimicrob Chemother"},{"key":"508_CR33","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B et al (2015) Ceftolozane\/Tazobactam plus Metronidazole for complicated intra-abdominal infections in an era of Multidrug resistance: results from a\u00a0randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462\u20131471","journal-title":"Clin Infect Dis"},{"key":"508_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01964-16","author":"E Temkin","year":"2017","unstructured":"Temkin E, Torre-Cisneros J, Beovic B et al (2017) Ceftazidime-Avibactam as salvage therapy for infections caused by Carbapenem-resistant organisms. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01964-16","journal-title":"Antimicrob Agents Chemother"},{"key":"508_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J et al (2018) Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a\u00a0randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18:285\u2013295","journal-title":"Lancet Infect Dis"},{"key":"508_CR36","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a\u00a0randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"},{"key":"508_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P et al (2016) Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute Pyelonephritis: RECAPTURE, a\u00a0phase 3 randomized trial program. Clin Infect Dis 63:754\u2013762","journal-title":"Clin Infect Dis"},{"key":"508_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","volume":"23","author":"H Wright","year":"2017","unstructured":"Wright H, Bonomo RA, Paterson DL (2017) New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect 23:704\u2013712","journal-title":"Clin Microbiol Infect"},{"key":"508_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","volume":"73","author":"GG Zhanel","year":"2013","unstructured":"Zhanel GG, Lawson CD, Adam H et al (2013) Ceftazidime-avibactam: a\u00a0novel cephalosporin\/beta-lactamase inhibitor combination. Drugs 73:159\u2013177","journal-title":"Drugs"},{"key":"508_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","volume":"74","author":"GG Zhanel","year":"2014","unstructured":"Zhanel GG, Chung P, Adam H et al (2014) Ceftolozane\/tazobactam: a\u00a0novel cephalosporin\/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74:31\u201351","journal-title":"Drugs"},{"key":"508_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H et al (2018) Imipenem-Relebactam and Meropenem-Vaborbactam: two novel Carbapenem-beta-Lactamase inhibitor combinations. Drugs 78:65\u201398","journal-title":"Drugs"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0508-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T05:44:09Z","timestamp":1605073449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0508-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0508-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]},"assertion":[{"value":"27 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Mischnik, C.\u00a0L\u00fcbbert und N.T.\u00a0Mutters geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}